Ontology highlight
ABSTRACT: Rationale
In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children.Objectives
To define T2-high asthma with easily accessible biomarkers and compare resulting phenotypes across all ages.Methods
In the multicentre clinical All Age Asthma Cohort (ALLIANCE), 1125 participants (n=776 asthmatics, n=349 controls) were recruited and followed for 2 years (1 year in adults). Extensive clinical characterisation (questionnaires, blood differential count, allergy testing, lung function and sputum induction (in adults)) was performed at baseline and follow-ups. Interleukin (IL)-4, IL-5 and IL-13 were measured after stimulation of whole blood with lipopolysaccharide (LPS) or anti-CD3/CD28.Measurements and main results
Based on blood eosinophil counts and allergen-specific serum IgE antibodies, patients were categorised into four mutually exclusive phenotypes: "atopy-only", "eosinophils-only", "T2-high" (eosinophilia + atopy) and "T2-low" (neither eosinophilia nor atopy). The T2-high phenotype was found across all ages, even in very young children in whom it persisted to a large degree even after 2 years of follow-up. T2-high asthma in adults was associated with childhood onset, suggesting early origins of this asthma phenotype. In both children and adults, the T2-high phenotype was characterised by excessive production of specific IgE to allergens (p<0.0001) and, from school age onwards, by increased production of IL-5 after anti-CD3/CD28 stimulation of whole blood.Conclusions
Using easily accessible biomarkers, patients with T2-high asthma can be identified across all ages delineating a distinct phenotype. These patients may benefit from therapy with biologicals even at a younger age.
SUBMITTER: Maison N
PROVIDER: S-EPMC9520028 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature
Maison Nicole N Omony Jimmy J Illi Sabina S Thiele Dominik D Skevaki Chrysanthi C Dittrich Anna-Maria AM Bahmer Thomas T Rabe Klaus Friedrich KF Weckmann Markus M Happle Christine C Schaub Bianca B Meyer Meike M Foth Svenja S Rietschel Ernst E Renz Harald H Hansen Gesine G Kopp Matthias Volkmar MV von Mutius Erika E Grychtol Ruth R Fuchs Oliver O Roesler Barbara B Welchering Nils N Kohistani-Greif Naschla N Kurz Johanna J Landgraf-Rauf Katja K Laubhahn Kristina K Liebl Claudia C Ege Markus M Hose Alexander A Zeitlmann Esther E Berbig Mira M Marzi Carola C Schauberger Christina C Zissler Ulrich U Schmidt-Weber Carsten C Ricklefs Isabell I Diekmann Gesa G Liboschik Lena L Voigt Gesche G Sultansei Laila L Nissen Gyde G König Inke R IR Kirsten Anne-Marie AM Pedersen Frauke F Watz Henrik H Waschki Benjamin B Herzmann Christian C Abdo Mustafa M Biller Heike H Gaede Karoline I KI Bovermann Xenia X Steinmetz Alena A Husstedt Berrit Liselotte BL Nitsche Catharina C Veith Vera V Szewczyk Marlen M Brinkmann Folke F Malik Aydin A Schwerk Nicolaus N Dopfer Christian C Price Mareike M Jirmo Adan Chari AC Habener Anika A DeLuca David S DS Gaedcke Svenja S Liu Bin B Calveron Mifflin-Rae MR Weber Stefanie S Schildberg Tom T van Koningsbruggen-Rietschel Silke S Alcazar Miguel M
The European respiratory journal 20220929 3
<h4>Rationale</h4>In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children.<h4>Objectives</h4>To define T2-high asthma with easily accessible biomarkers and compare resulting phenotypes across all ages.<h4>Methods</h4>In the multicentre clinical All Age Asthma Cohort (ALLIANCE), 1125 participants (n=776 asthmatics, n=349 controls) were recruited and followed for 2 years ...[more]